Literature DB >> 9508059

Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree.

R Moslehi1, S Langlois, I Yam, J M Friedman.   

Abstract

Hyperkalemic periodic paralysis (HPP) is caused by mutations of the adult skeletal muscle sodium channel (SCN4A) gene on chromosome 17. Malignant hyperthermia (MH) is a genetically heterogeneous autosomal-dominant disorder occurring in association with various neuromuscular diseases or without other apparent abnormalities. In some families, MH is associated with mutations of a calcium release channel (RYR1) gene on chromosome 19. In other families, linkage of this disorder to the SCN4A gene on chromosome 17 has been suggested. We report on linkage analysis in a family in which both HPP and MH are inherited as autosomal-dominant traits. Two polymorphisms within the SCN4A locus, an RFLP and a (C-A)n repeat, were typed on multiple family members. The findings were consistent with linkage of the polymorphic markers within the SCN4A gene to both HPP (Zmax = 6.79 at theta = 0.0) and MH (Zmax = 1.76 at theta = 0) in this family. Our data provide further evidence that MH is linked to the SCN4A locus in some families.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508059

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  6 in total

Review 1.  Unraveling monogenic channelopathies and their implications for complex polygenic disease.

Authors:  J Jay Gargus
Journal:  Am J Hum Genet       Date:  2003-03-07       Impact factor: 11.025

2.  A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation.

Authors:  S Bendahhou; T R Cummins; A F Hahn; S Langlois; S G Waxman; L J Ptácek
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 3.  Muscle channelopathies and critical points in functional and genetic studies.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 4.  PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria L Alvarellos; Ellen M McDonagh; Sephalie Patel; Howard L McLeod; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-12       Impact factor: 2.089

Review 5.  Neurological channelopathies.

Authors:  T D Graves; M G Hanna
Journal:  Postgrad Med J       Date:  2005-01       Impact factor: 2.401

6.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.